MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測

Same-Day Veterinary AST: Beat the 72-Hour Culture Lag

info — Fri, 09 Oct 2026 16:09:39 +0000

Executive Summary

Veterinary medicine stands at a critical threshold. As the global veterinary community prepares for WSAVA 2026 (Warsaw, Oct 13–15) and FASAVA 2026 (Taipei, Oct 31–Nov 2), the mounting threat of veterinary antimicrobial resistance (AMR in animal hospitals) has moved from a theoretical concern to a daily operational crisis. Emergency and critical care clinicians frequently face severe canine and feline infections that demand immediate intervention. Yet traditional reference laboratory workflows force a dangerous delay: clinicians wait 3 to 5 days for standard culture and susceptibility results.

To bridge this window, modern companion animal practice needs a shift toward point-of-care testing (POCT). Microfluidic rapid AST (Antimicrobial Susceptibility Testing) helps hospital medical directors and clinical teams move away from empirical broad-spectrum antibiotic use and toward precise, same-day targeted therapy. By combining rapid pathogen identification with true phenotypic susceptibility testing on the hospital benchtop, microfluidic platforms provide the decision support needed to uphold global antimicrobial stewardship standards.

The Clinical Bottleneck: When 72-Hour Referral Lab Delays Fuel Empirical Prescribing

In small animal practice, complex bacterial infections carry high clinical stakes. Acute canine and feline infectious diseases, such as complicated lower urinary tract infections (UTIs), persistent canine pyoderma, feline upper respiratory tract infections, and post-surgical septic complications, all require rapid treatment decisions.

When samples are sent to external reference laboratories, traditional broth microdilution or disk diffusion testing introduces a long lag phase:

Logistical transport lags. Courier pickup schedules, cold-chain transport, and laboratory intake consume 24 to 48 hours before incubation even begins.
Bacterial growth timeframes. Standard culture requires long incubation to establish visible colony-forming units (CFUs) and evaluate inhibition zones.
The empirical dilemma. Faced with a symptomatic patient and an anxious owner, clinicians cannot leave severe infections untreated for 72+ hours, so empirical broad-spectrum therapy is started.

This reliance on empirical treatment increases selection pressure for multidrug-resistant (MDR) pathogens in companion animal populations. High-risk strains, including Methicillin-Resistant Staphylococcus pseudintermedius (MRSP) and Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia coli, are now regularly isolated in animal hospitals. When an empirical antibiotic fails against an undetected MDR pathogen, the patient suffers prolonged morbidity, costs escalate, and resistant strains spread within the hospital and the community.

Benchtop Microfluidic POCT: The Technological Leap in Veterinary Rapid AST

Solving this diagnostic delay means moving testing from distant central laboratories to the point of care. Microfluidic technology is a major advance in canine and feline infectious disease POCT, replacing slow benchtop cultures with precise microscale engineering.

Understanding the MedFluid NAST Platform

The MedFluid NAST platform is purpose-built for in-clinic, point-of-care operation. Unlike complex central lab automation systems, it combines two sequential analytical steps in a single benchtop workflow:

Rapid pathogen nucleic acid screening. Rapid identification of targeted bacterial pathogens directly from clinical samples.
Phenotypic antimicrobial susceptibility testing (AST). Real-time observation of live bacterial responses to specific antibiotic panels at clinically relevant concentrations.

On-Chip Mechanism and Microcolony Tracking

The core of MedFluid’s microfluidic architecture is how it handles biological fluid dynamics at the nanoliter scale:

Single-cell isolation and microchamber arrays. Clinical specimens are captured in microfluidic channels, encapsulating bacteria in microchambers designed for controlled growth.
Real-time optical microcolony tracking. Instead of waiting days for visible turbidity or large colonies, the system uses high-resolution optical tracking to observe microcolony formation within hours.
Phenotypic precision. By directly observing bacterial cell division or growth inhibition in the presence of antibiotics, the system delivers definitive phenotypic susceptibility data, not merely genotypic resistance-marker predictions, in a fraction of the traditional turnaround time.

Operationalizing Same-Day Precision Medicine in Animal Hospitals

Bringing microfluidic rapid AST into regular clinical practice turns a reactive multi-day wait into a streamlined, same-day protocol.

The in-clinic workflow

Sample collection and preparation. Collect standard clinical samples (urine, wound swabs, otic exudates, or aspirates) during the initial patient examination.
On-chip cartridge loading. Transfer the prepared sample into the dedicated single-use microfluidic cartridge containing pre-loaded antibiotic panels.
Benchtop run on the O-in analyzer. Insert the cartridge into the MedFluid O-in analyzer. The automated system manages fluidic control, incubation, microcolony optical tracking, and data analysis without requiring specialized laboratory technician expertise.
Actionable results and same-day prescribing. Within hours, the clinician receives an unambiguous phenotypic susceptibility report, supporting an immediate, evidence-based narrow-spectrum prescription during the initial visit.

Practice management benefits

Global Stewardship and Taiwan’s Leadership at FASAVA 2026 Taipei

Adopting point-of-care rapid AST aligns with current global veterinary initiatives. Both the World Small Animal Veterinary Association (WSAVA) and the Federation of Asian Small Animal Veterinary Associations (FASAVA) have emphasized actionable antimicrobial stewardship guidelines to combat regional AMR escalation.

Key stewardship imperatives for the 2026 congresses include:

Eliminating unnecessary broad-spectrum use. Reserving highest-priority critically important antimicrobials (HPCIAs) for cases where phenotypic resistance to first-line agents is proven.
Diagnostic first principles. Establishing pathogen identity and antimicrobial susceptibility before committing to long-term therapy.
Regional innovation. As Taipei prepares to host FASAVA 2026, Taiwan’s biomedical microfluidics sector is showing how advanced microfabrication can solve complex clinical diagnostic challenges. Local innovations like MedFluid offer practice leaders worldwide a scalable model for modern point-of-care diagnostics.

Clinician FAQs on In-Clinic Microfluidic Rapid AST

How does microfluidic AST turnaround time compare to traditional reference labs?

MedFluid at WSAVA Congress 2026: See the NAST System Live in Warsaw!

info — Thu, 17 Sep 2026 11:37:50 +0000

MedFluid is thrilled to announce our upcoming participation in the WSAVA Congress 2026 in Warsaw, Poland!

This October, we are proud to showcase our latest Made-in-Taiwan veterinary innovation to professionals worldwide: NAST, the original in-clinic antibiotic susceptibility test.Historically, veterinary practices have had to wait 3 to 7 days for external laboratory antibiotic test results. Powered by MedFluid’s proprietary rapid microfluidic testing technology, the NAST system empowers clinics to obtain highly precise data in a fraction of the time, ensuring patients receive the most effective treatment right when they need it.

Core Advantages of the NAST System:

⏱️ 6-Hour Results (not 3-7 days) Dramatically reduce the waiting period. By delivering results in just 6 hours, veterinarians can confidently adjust treatment plans based on scientific data within the very same shift.
📊 True MIC Values (not just S / I / R) Move beyond broad Susceptible / Intermediate / Resistant classifications. NAST provides true Minimum Inhibitory Concentration (MIC) values, enabling precise and targeted antimicrobial stewardship.
⚙️ Cartridge-Based (load and walk away) Designed for seamless integration into your busy clinic. Simply load the sample cartridge and walk away—allowing your staff to focus on patient care while the system handles the testing.

【Event Details】

Date: 13–15 October 2026
Location: EXPO XXI Convention Center, Warsaw, Poland
MedFluid Booth: #89

Whether you are a veterinary professional looking to upgrade your in-house diagnostics or a distributor seeking innovative partnerships, the MedFluid team looks forward to welcoming you to Booth #89!

For more details on NAST and our underlying technology, visit medfluid.com.tw.

The post MedFluid at WSAVA Congress 2026: See the NAST System Live in Warsaw! first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

How to Tackle Veterinary AMR with Rapid Microfluidic POCT

info — Tue, 15 Sep 2026 12:34:48 +0000

Veterinary antimicrobial resistance (AMR) is a major threat to animal health today, driving the need for Rapid Microfluidic POCT solutions. Specifically, animal hospitals face intense pressure during emergencies. In these critical moments, fast action is vital. However, standard lab cultures force a 3 to 5-day wait before clinics get useful data.

As a result, vets must rely on broad-spectrum antibiotics based on guesswork. By the time lab results return, the infection may have worsened. Furthermore, the pet might have received unnecessary drugs. Consequently, this cycle makes AMR even worse. Therefore, adopting Rapid Microfluidic POCT is essential for better care.

The Diagnostic Dilemma: Empirical Treatment vs. Rising Veterinary Antimicrobial Resistance

Today, multi-drug resistant (MDR) infections are rising in dogs and cats. Indeed, vets see more complex cases that resist standard treatments. For example:

Complicated UTIs: Stubborn infections that need precise drugs.
Pyoderma: Repeated skin issues, often from resistant bacteria.
Sepsis: Severe emergencies where every wasted hour increases the risk of death.

Addressing this problem requires real action. By focusing on AMR in animal hospitals, practitioners can use specific clinical protocols. Ultimately, this prioritizes hard evidence over guesswork.

Rapid Microfluidic POCT: MedFluid’s NAST & O-in Innovation

MedFluid is changing the diagnostic timeline. We offer veterinary rapid AST technology built for in-clinic use. Unlike bulky lab machines, these MedFluid Benchtop Solutions are made for point-of-care settings.

The NAST Platform

The NAST (Nest-Shape Antibiotic Susceptibility Testing) platform is MedFluid’s core microfluidic tool. Specifically, it combines two crucial steps:

Rapid Nucleic Acid screening to identify pathogens.
Phenotypic testing to find the best antibiotic.

Moreover, the system uses the MedFluid O-in for real-time microcolony monitoring. By watching bacteria grow microscopically, the platform delivers susceptibility profiles in hours, not days.

Clinical Impact for Veterinary Practices

Implementing rapid tests directly improves practice efficiency.

Same-Day Therapy: First, vets can stop guessing and start prescribing precise antibiotics immediately.
Client Trust: Second, showing pet owners rapid, clear data improves treatment compliance.
Workflow Efficiency: Finally, clinics no longer waste time shipping samples or chasing delayed lab reports.

Global Industry Context & FASAVA 2026 Outlook

This shift toward rapid diagnostics clearly supports global veterinary guidelines. For instance, organizations like the World Small Animal Veterinary Association and the Federation of Asian Small Animal Veterinary Associations strongly advocate for better stewardship.

As the industry prepares for FASAVA 2026 in Taipei, Taiwanese microfluidic technology is gaining global attention.Consequently, these tools are helping local clinics lead the way in animal health.

Conclusion & Call to Action

In conclusion, fighting veterinary AMR requires a new approach to diagnostics. By adopting MedFluid’s NAST platform and Rapid Microfluidic POCT, clinics can deliver truly precise medicine. For demonstrations or regional distribution inquiries, please contact us today:https://medfluid.com.tw/info@medfluid.com.tw

Frequently Asked Questions (FAQ) for Veterinary Clinicians

Question	Clinical Insight
What is the expected turnaround time?	The platform delivers results within hours, significantly faster than the 72-hour reference lab standard.
What are the sample requirements?	Designed for in-clinic use, the system processes standard clinical samples directly at the point of care.
Does it provide phenotypic or genotypic results?	The NAST platform integrates both, providing rapid identification and phenotypic susceptibility profiles.
How does it integrate into a standard clinic?	It is a compact, benchtop POCT solution, avoiding the need for bulky laboratory infrastructure.

The post How to Tackle Veterinary AMR with Rapid Microfluidic POCT first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

From Days to Hours: Transforming Veterinary Care with Microfluidic Rapid AST

info — Mon, 07 Sep 2026 07:00:19 +0000

The rise of veterinary antimicrobial resistance (AMR) represents one of the most significant challenges in modern veterinary medicine. For practitioners on the front lines, the clinical need for rapid, accurate diagnosis of infectious diseases has never been more urgent. When a pet presents with a severe infection, every hour matters. However, the current diagnostic landscape often forces a difficult choice between immediate, unguided treatment and a long wait for precise data.

Why Traditional Culture and Susceptibility Tests Fail Emergency Pet Care

In the high-stakes environment of emergency veterinary care, traditional culture and susceptibility tests are frequently inadequate. These conventional methods typically require a 3-5 day turnaround time to provide actionable results.

During this multi-day window, veterinarians are often compelled to rely on empiric antibiotic therapy. This “best guess” approach carries significant risks:

Potential for treatment failure if the pathogen is resistant to the selected drug.
The inadvertent acceleration of antimicrobial resistance within the patient and the local environment.
Increased costs and prolonged hospitalization for the pet owner.

Revolutionary Microfluidic POCT: How MedFluid’s Cartridge & Analyzer Work

MedFluid is bridging this diagnostic gap through its core microfluidic technologies: the O-in platform and NAST. By integrating complex laboratory processes into a streamlined Point-of-Care Testing (POCT) system, MedFluid enables animal hospitals to perform sophisticated testing on-site.

The system utilizes a specialized Cartridge and Analyzer setup designed for rapid microfluidic testing, allowing for immediate detection and analysis without the need for automated lab machinery or extensive laboratory infrastructure.

Canine & Feline Infectious Disease Nucleic Acid Detection

The MedFluid platform provides highly sensitive nucleic acid detection tailored for common and critical canine a

nd feline infectious diseases. This allows for the immediate identification of pathogens at the molecular level, ensuring that the primary cause of infection is pinpointed early in the clinical visit.

Rapid Antibiotic Susceptibility Testing (AST) in Hours, Not Days

The true breakthrough of MedFluid’s technology lies in its ability to deliver Rapid Antibiotic Susceptibility Testing (AST). Rather than waiting nearly a week for bacterial growth, the rapid microfluidic system analyzes phenotypic responses in a fraction of the time. This shifts the turnaround time from several days to just a few hours, allowing for targeted, evidence-based antibiotic selection within the same day of admission.

Clinical Benefits for Animal Hospitals

Implementing microfluidic POCT offers transformative advantages for the modern animal hospital workflow:

Workflow Optimization: On-site testing reduces the logistical burden of shipping samples to external labs and accelerates the clinical decision-making process.
Client Communication: Providing pet owners with rapid, definitive answers fosters trust and allows for immediate discussions regarding treatment plans and prognosis.
Antimicrobial Stewardship: By ensuring the right drug is used at the right time, hospitals can actively participate in global efforts to combat veterinary AMR, preserving the efficacy of existing antibiotics.

Global Trends and Industry Standards

As veterinary medicine becomes increasingly data-driven, the adoption of rapid diagnostics is aligning with emerging international standards. MedFluid is committed to staying at the forefront of these global trends, connecting with the international veterinary community at major upcoming events, such as FASAVA 2026 Taipei. These forums highlight the shift toward precision medicine and the integration of microfluidic technology into standard clinical protocol

s worldwide.

Frequently Asked Questions (FAQ)

How long does a MedFluid AST result take compared to traditional labs?

While traditional labs typically take 3-5 days, MedFluid’s rapid microfluidic technology provides AST results in just hours, enabling same-day targeted therapy.

What species are currently supported by the O-in platform?

The platform is specifically optimized for canine and feline infectious disease detection and susceptibility testing.

Does this technology require specialized lab technicians?

No. The Cartridge and Analyzer system is designed for ease of use within a standard animal hospital environment, streamlining the rapid diagnostic workflow for existing staff without requiring large automated laboratory equipment.

Conclusion

The transition from empiric treatment to precision medicine is essential for the future of veterinary health. By reducing diagnostic wait times from days to hours, MedFluid’s O-in and NAST technologies empower veterinarians to fight antimicrobial resistance effectively while providing the highest standard of care for their patients.

Experience the future of veterinary diagnostics.

Explore the MedFluid O-in system and connect with our team today regarding clinical trials and distribution opportunities.

The post From Days to Hours: Transforming Veterinary Care with Microfluidic Rapid AST first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

EU Veterinary Antibiotic Regulations Explained: A New Perspective on Companion Animal Treatment in the Era of Antimicrobial Resistance

agent30 — Mon, 01 Sep 2025 06:45:43 +0000

Under the One Health framework, the world is responding to the challenge of Antimicrobial Resistance (AMR) at an unprecedented pace. This issue not only concerns human health but is also closely tied to animal health and environmental protection. As a global leader in regulatory standards, the European Union has introduced the Regulation (EU) 2019/6 on Veterinary Medicinal Products, along with its related provisions, which are beginning to bring profound impacts on the veterinary profession. This article provides an in-depth analysis of these regulations and explores how veterinarians can adopt innovative tools to stay ahead in this era of transformation.

1. EU Regulatory Trends: Precision Medicine and the Role of Companion Animals

Although the market authorization framework for veterinary medicines resembles that of human pharmaceuticals, significant differences exist in industry scale, markets, and target populations. Veterinary medicine must serve a highly diverse set of species, primarily divided into food-producing animals and companion animals. While food animals account for the majority of antibiotic use, the new regulations place increasing emphasis on antimicrobial use in companion animals.
The European Medicines Agency (EMA) categorizes antibiotics into four classes (A, B, C, D) based on their risk to public health and their value in veterinary medicine. These categories apply to all animal species and define clear principles for antimicrobial stewardship:

Category A (Avoid): These antibiotics are generally prohibited for animal use. In exceptional cases—such as therapeutic gaps—they may be used in companion animals, but always under strict conditions and ideally guided by Antimicrobial Susceptibility Testing (AST).
Category B (Restrict): Considered critically important for veterinary medicine, these antibiotics may only be prescribed if no Category C or D alternatives are effective. Their use should likewise be supported by AST results.
Category C (Caution): These antibiotics should only be considered if no suitable Category D option is available.
Category D (Prudence):Recommended as the first-line treatment whenever possible.

This framework demonstrates that antibiotic selection is no longer solely at a veterinarian’s discretion but must follow a stepwise hierarchy of use. Notably, EU member states such as the Netherlands, Belgium, and Denmark now require veterinarians by law to perform AST before prescribing Category B (e.g., fluoroquinolones) or Category A antibiotics (e.g., 3rd/4th generation cephalosporins). This confirms that AST prior to prescription is becoming an inevitable global trend.

2. The Urgency of AMR and the Central Role of AST

The most critical consequence of antibiotic misuse is the emergence of bacterial strains that develop co-resistance or cross-resistance to antibiotics used in human medicine, which can then spread across species. This poses serious risks not only to animal health but also to human health. Studies clearly demonstrate a positive correlation between veterinary antibiotic consumption and antimicrobial resistance in animals, as well as strong associations with resistance in WHO priority human pathogens.
For this reason, the EU emphasizes that prescriptions must be clinically justified. Any antibiotic use must follow clinical examination or health assessment, and whenever possible, pathogen identification and susceptibility testing should precede treatment. This principle applies to all antibiotic categories, not just A or B.
However, traditional AST methods are time-consuming, often requiring several days to produce results. In urgent clinical situations involving companion animals, veterinarians cannot always afford to wait, which can lead to empirical prescribing and subsequently increase the risk of resistance development.

3. Our Solution: Rapid and Accurate AST for Companion Animal Veterinarians

This is precisely the challenge that MedFluid’s NAST system was designed to address. Our diagnostic instrument and consumables for antimicrobial susceptibility testing are tailored for veterinary clinics, delivering accelerated and reliable AST results. This enables veterinarians to:

Comply with regulatory requirements:Our solution provides rapid AST data, ensuring veterinarians remain compliant with increasingly strict regulations, particularly in regions where AST is now mandatory prior to prescribing critical antibiotics.
Enable precision prescribing:Instead of relying solely on experience, symptoms, or medical history, our system provides sample-based susceptibility data to guide every clinical decision—optimizing treatment outcomes and potentially shortening recovery times.
Combat AMR at its roots:By reducing unnecessary or inappropriate use of antibiotics, our platform directly helps slow the emergence and spread of resistant bacterial strains.

The evolution of EU regulations signals a global shift: antibiotic use will be subject to stricter control, while precision medicine will become the new norm. MedFluid’s NAST system stands as the ideal tool for veterinarians navigating this new era. By leveraging technology, we can empower veterinarians to safeguard companion animal health while contributing to the worldwide fight against antimicrobial resistance.

References

Allel, K., et al., 2023. Global antimicrobial-resistance drivers: an ecological country-level study at the human-animal interface. Lancet Planet Health 7, e291-303.
European Medicines Agency (EMA). (2020). Categorisation of antibiotics used in animals promotes responsible use to protect public and animal health. EMA/688114/2020.
European Medicines Agency (EMA). (2022a). Antimicrobial Sales and Use (ASU) data reporting protocol Part 1 Reporting volume of sales. Implementation of the requirements of Regulation (EU) 2019/6 for the collection of data on antimicrobial medicinal products used in animals. EMA/258839/2022.
European Medicines Agency (EMA). (2022b). Sales of veterinary antimicrobial agents in 31 European countries in 2021 – Trends from 2010-2021. Twelfth ESVAC report. Publications Office of the European Union.
Ministry of Health, Welfare and Sport. Animal Health Register, The Netherlands. Regelingdiergeneeskundigen.
Reg. (EU) 2019/6, 2019. Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC. Official Journal of the European Union, L 4, 7.1.2019.
Schmerold, I., Geijlswijk, I. van, & Gehring, R. (2023). European regulations on the use of antibiotics in veterinary medicine. European Journal of Pharmaceutical Sciences, 189, 106473.
World Health Organisation (WHO). (2017). One Health.
World Health Organisation (WHO). (2019). Critically Important Antimicrobials for Human Medicine – 6th revision 2018. Geneva: World Health Organization.

The post EU Veterinary Antibiotic Regulations Explained: A New Perspective on Companion Animal Treatment in the Era of Antimicrobial Resistance first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

What Every New Dog Parent Must Understand: A Medical and Ethical Perspective

agent30 — Mon, 11 Aug 2025 06:56:22 +0000

https://medium.com/@medfluid/what-every-new-dog-parent-must-understand-a-medical-and-ethical-perspective-a0ba2de48f02

The post What Every New Dog Parent Must Understand: A Medical and Ethical Perspective first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

Urinary Tract Infections (UTIs) in Dogs and Cats: Insights from a Hong Kong Study on Antimicrobial Resistance

admin — Fri, 21 Mar 2025 05:15:58 +0000

Urinary tract infections (UTIs) are common clinical problems in both dogs and cats, often leading to recurrent cases of cystitis and pyelonephritis. In addition to following antimicrobial treatment guidelines¹, regional epidemiological analysis can offer valuable and specific insights to help veterinarians better understand antimicrobial resistance (AMR) trends and make informed treatment decisions.

In 2023, a retrospective study² on UTIs in companion animals was published in Hong Kong, aiming to evaluate the relationship between clinical antimicrobial usage and bacterial resistance patterns from 2018 to 2020. The study analyzed urine culture data from 15,449 canine and feline samples collected over three years. Of these, 5,731 samples (37%) yielded positive bacterial cultures, with dogs accounting for 55.2% and cats for 44.8% of the positive cases.

15449 canine and feline urine samples

2018

2019

2020

Total

No growth

3591

(62%)

2918

(62.4%)

3209

(64.3%)

9718

(63%)

Positive for selection

2196

(38%)

1752

(37.6%)

1783

(35.7%)

5731

(37%)

However, only 311 isolates (11%) out of the 5,731 culture-positive cases were fully susceptible to all tested antimicrobials, while a concerning 56% exhibited multidrug resistance. This highlights the growing complexity in empirical prescribing and the difficulty in selecting effective treatments against diverse bacterial strains.

The study found that the types of pathogens causing UTIs in dogs and cats were relatively consistent. For dogs, the top five bacterial pathogens were Escherichia coli, Proteus spp., Staphylococcus spp., Enterococcus spp., and Klebsiella spp., collectively accounting for approximately 90% of the annual positive samples. For cats, the dominant pathogens included E. coli, Enterococcus spp., Staphylococcus spp., Pseudomonas spp., Proteus spp., and Klebsiella spp., comprising 95% of the positive cases in the same period.

Of particular concern, these common uropathogens demonstrated widespread resistance to first-line antimicrobial agents such as amoxicillin, ampicillin, and trimethoprim-sulfamethoxazole. For example:

E. coli: The most frequently isolated pathogen in feline UTI cases, accounting for 45–49% of positive cat samples annually. It also comprised 34–39% of dog isolates. Resistance to amoxicillin and ampicillin reached 47% in cats and 50% in dogs.
Klebsiella spp.: Exhibited extremely high resistance rates to amoxicillin and ampicillin (>96%) in both species, and moderate resistance (50–60%) to cephalosporins, fluoroquinolones, and penicillins.
Staphylococcus spp.: Showed resistance rates of 78% to amoxicillin and 60% to ampicillin.
Enterococcus spp.: Demonstrated over 95% resistance to trimethoprim-sulfamethoxazole. Moreover, as cephalosporins are ineffective against Enterococci, careful selection of alternative antimicrobials becomes critical to avoid accelerating resistance.

Even more alarming, multidrug resistance—defined as resistance to three or more antimicrobial classes—was observed in 56% of positive cultures, with 68% originating from canine samples. Despite these high resistance rates, the three-year data showed that pathogen distribution and resistance trends remained relatively stable throughout the study period.

In conclusion, this study clearly identifies the predominant pathogens associated with UTIs in dogs and cats in Hong Kong, along with their widespread resistance to first-line antimicrobials—especially the high rate of multidrug resistance. These findings serve as an important alert to clinicians when selecting empirical treatments. While the resistance trends remained stable during the study period, veterinarians should continue to monitor local AMR patterns closely. Whenever possible, bacterial culture and sensitivity testing should be encouraged to guide more accurate and effective antimicrobial choices.

The research team also emphasized that promoting judicious antibiotic use, alongside tools such as diagnostic testing systems, could support veterinarians in making more informed therapeutic decisions—ultimately contributing to the effort to curb the spread of antimicrobial resistance.

References:

J. Scott Weese et. al., International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats, The Veterinary Journal, 2019. https://doi.org/10.1016/j.tvjl.2019.02.008
Olivia S. K. Chan et. al., A Retrospective Study of Antimicrobial Resistant Bacteria Associated with Feline and Canine Urinary Tract Infection in Hong Kong SAR, China—A Case Study on Implication of First-Line Antibiotics Use, Antibiotics, 2022, 11, 1140. https://doi.org/10.3390/antibiotics11091140

At Medfluid, we create simple and reliable tools to help veterinarians find the right treatment for bacterial infections—making care more precise, and helping stop the spread of antimicrobial resistance.
By sharing the latest scientific knowledge, we hope to inspire thoughtful antibiotic use and walk alongside veterinarians as a trusted partner in protecting animal health.

The post Urinary Tract Infections (UTIs) in Dogs and Cats: Insights from a Hong Kong Study on Antimicrobial Resistance first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

A wonderful serenity has taken possession3

admin — Fri, 21 Mar 2025 05:15:35 +0000

chemist,scientist hand dropping chemical liquid into test tube, science research and development concept

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.

In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.
Nullam dictum felis eu pede mollis pretium.
Integer tincidunt.

Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

Nam eget dui.

Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.

The post A wonderful serenity has taken possession3 first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

A wonderful serenity has taken possession2

admin — Fri, 21 Mar 2025 05:13:31 +0000

chemist,scientist hand dropping chemical liquid into test tube, science research and development concept

In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.
Nullam dictum felis eu pede mollis pretium.
Integer tincidunt.

Nam eget dui.

The post A wonderful serenity has taken possession2 first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.

A wonderful serenity has taken possession

agent11 — Fri, 20 Sep 2024 09:12:16 +0000

chemist,scientist hand dropping chemical liquid into test tube, science research and development concept

In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.
Nullam dictum felis eu pede mollis pretium.
Integer tincidunt.

Nam eget dui.

The post A wonderful serenity has taken possession first appeared on MedFluid醫流體-Microfluidics專利微流體｜POCT快速診斷｜AST獸醫抗生素用藥檢測｜Molecular Diagnosis核酸檢測.